A phase I multiple ascending dose (MAD) study of PL265
Latest Information Update: 05 Jul 2017
At a glance
- Drugs PL 265 (Primary)
- Indications Cancer pain; Dry eyes; Neuropathic pain; Ocular pain
- Focus Adverse reactions
Most Recent Events
- 05 Jul 2017 New trial record
- 29 Jun 2017 According to a Pharmaleads media release, data from this study is expected in 2018.